Overview

Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect Ulimorelin in patients with enteral feeding intolerance.
Phase:
Phase 2
Details
Lead Sponsor:
Lyric Pharmaceuticals
Treatments:
Metoclopramide